Why XORTX Therapeutics stock exploded in volume after its $700m gout market update
XORTX Therapeutics shares climbed 15.7% as trading volume surged above seven million shares after the company outlined plans to file an FDA IND for XRx-026 in the fourth quarter, but funding requirements remain a critical part of the development story.